Skip to main content

Find Drugs & Conditions

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

FDA Grants Accelerated Approval to Ziihera (zanidatamab-hrii) for the Treatment of HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii)...

UCB Receives U.S. FDA Approval for Bimzelx (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate to Severe Hidradenitis Suppurativa

Brussels (Belgium),  November 20, 2024 – 07:00 (CET) – UCB, a global biopharmaceutical company, today announced that the U.S. Food...

FDA Approves Revuforj (revumenib) for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) as the first and...

Taking a GLP-1 Medication? Here's Tips to Holiday Eating

So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle...

Opioid Use Treatment at Intervention Clinics Continues to Rise for Third Year

Opioid use disorder (OUD) treatment continued to increase in intervention clinics in the third year of implementation of the Massachusetts office-based...

No Long-Term Cognitive Effects Seen for Menopausal Hormone Therapy

Menopausal hormone therapy (mHT) is not associated with long-term cognitive effects versus placebo, according to a study published online Nov. 21 in PLOS...

FDA Approves Nerivio for Migraine Treatment in Children Aged 8 Years and Older

The U.S. Food and Drug Administration has expanded the age indication for Nerivio, making it the first and only remote electrical neuromodulation (REN)...

2010 to 2021 Saw Rise in Postpartum Depression

Diagnosis of postpartum depression increased significantly across all racial and ethnic groups and body mass index categories over the past decade, according...

Bird Flu Virus in Canadian Teen Shows Mutations That Could Help It Spread Among Humans

In a development that health experts have warned might come, Canadian officials report that the bird flu virus isolated from a sick teen in Vancouver shows...

Short-Term Hormone Therapy for Menopause Won't Harm Women's Brains

Four years of hormone replacement therapy to help women deal with menopausal symptoms causes no harm to the brain, even over the long term, new research...

Flavored Vapes Behind Big Surge in U.S. E-Cigarette Sales

FRIDAY, Nov. 22, 2024 — E-cigarettes flew off store shelves between 2019 and 2023, and 80% were in youth-friendly flavors like fruit, candy, mint...

First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV

HAYWARD, Calif., Nov. 21, 202. Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first patient...

Mxbbb Issues Voluntary Nationwide Recall of Umary Acid Hyaluronic Due to the Presence of Diclofenac and Omeprazole

MXBBB is voluntarily recalling 1 lot of UMARY ACID HYALURONIC, 30 CAPLETS 850 MG to the consumer level. The products have been found to have omeprazole...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

BRUSSELS, Belgium and CAMBRIDGE, Mass. – November 19, 2024 – UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed...

Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling

Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced...

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

PASADENA, Calif.–(BUSINESS WIRE)–Nov. 18, 2024– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New...

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

(BUSINESS WIRE)--Nov. 18, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has...

Is It Heartburn or a Heart Condition? An Expert Explains

You've loaded up on goodies while at a family gathering, and you suddenly feel chest pains. Is it heartburn or something worse? Being able to tell the...

Read more news...

Recently Added

Recently added consumer and prescribing information: Revuforj, Danziten, Aucatzyl, Emrosi, Imuldosa, Hympavzi, Flyrcado, Otulfi, Tecentriq Hybreza, Pavblu

For Consumers

For Professionals

For Researchers

Latest FDA New Drug Approvals

  • Ziihera Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody for the treatment of HER2-positive biliary tract cancer.
  • Revuforj Revuforj (revumenib) is a first-in-class menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine...
  • Danziten Danziten (nilotinib tartrate) is a kinase inhibitor used for the treatment of Philadelphia chromosome positive chronic myeloid leukemia.

More FDA approvals

Drugs in Development (Not yet approved)

  • Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...

More drugs in development